Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Crenshaw, Donna G ^a   Asin, Karen ^b   Gottschalk, William K ^a   Liang, Zhifeng ^c   Zhang, Nanyin ^c   Roses, Allen D ^a  

^a Zinfandel Pharmaceuticals   (United States)

^b TAKEDA DEVELOPMENT CENTER AMERICAS   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BOLD SIGNAL; BRAIN FUNCTION; CONNECTOME; CONSCIOUSNESS; CONTROLLED STUDY; DRUG EFFECT; HIPPOCAMPAL CA1 REGION; HYPOTHALAMUS; LOW DRUG DOSE; NEUROMODULATION; NONHUMAN; RAT; RESTING STATE NETWORK; SUBTHALAMUS; TREATMENT DURATION; ANIMAL; BODY WEIGHT; BRAIN; DOSE RESPONSE; DRUG EFFECTS; HIPPOCAMPUS; MALE; NERVE CELL NETWORK; PHYSIOLOGY; REST; WISTAR RAT;

RATTUS;

ANIMALS; BODY WEIGHT; BRAIN; CONSCIOUSNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; MALE; NERVE NET; RATS; RATS, WISTAR; REST; THIAZOLIDINEDIONES;

EID: 84923238696     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117973     Document Type: Article

References (58)

1. Alzheimer's Association (2010) Changing the Trajectory of Alzheimer's Disease: A National Imperative (2010). Chicago, Il: Alzheimer 's Association. Available: http://www.alz.org/documents-custom/ trajectory.pdf. PMID: 25506974
2. Grossman SL, Lessem J (1997) Mechanisms and clinical effects of thiazolidinediones. Expert Opin Investig Drugs 6: 1025-1040. PMID: 15989661
3. Mukherjee R, Jow L, Croston GE, Paterniti JR (1997) Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 272: 8071-8076. PMID: 9065481
4. Bogacka I, Xie H, Bray GA, Smith SR (2005) Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54: 1392-1399. PMID: 15855325
5. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, et al. (2009) PPARγ stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int 55: 496-504. doi: 10.1016/j.neuint.2009.05.001 PMID: 19442697
6. Strum JC, Shehee R, Virley D, Richardson J, Mattie M, et al. (2007) Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 11: 45-51. PMID: 17361034
7. Vasudevan AR, Balasubramanyam A (2004) Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 6: 850-863. PMID: 15684639
8. Heneka MT, Landreth GE (2007) PPARs in the brain. Biochim Biophys Acta 1771: 1031-1045. PMID: 17569578
9. Nicolakakis N, Hamel E (2010) The nuclear receptor PPARγ as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease. Front Aging Neurosci 2: 21. doi: 10.3389/fnagi.2010. 00021 PMID: 20725514
10. Papadopoulos P, Rosa-Neto P, Rochford J, Hamel E (2013) Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's Disease with combined amyloid-β and cerebrovascular pathology. PLoS One 8: e68612. doi: 10.1371/journal.pone.0068612 PMID: 23874687
11. Abbatecola AM, Lattanzio F, Molinari AM, Cioffi M, Mansi L, et al. (2010) Rosiglitazone and cognitive stability in older individuals with Type 2 Diabetes and Mild Cognitive Impairment. Diabetes Care 33: 1706-1711. doi: 10.2337/dc09-2030 PMID: 20435794
12. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G (2011) A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 68: 45-50. doi: 10.1001/archneurol.2010.229 PMID: 20837824
13. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, et al. (2010) Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: Results from a randomized, double-blind, placebocontrolled phase III study. Dement Geriatr Cogn Disord 30: 131-146. doi: 10.1159/000318845 PMID: 20733306
14. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T (2009) Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and Mild Cognitive Impairment with Diabetes Mellitus. J Am Geriatr Soc 57: 177-179. doi: 10.1111/j.1532-5415.2009.02067.x PMID: 19170800
15. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, et al. (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6: 246-254. PMID: 16446752
16. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, et al. (2010) Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32: 1626-1633
17. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, et al. (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13: 950-958. PMID: 16286438
18. Miglio G, Rattazzi L, Rosa AC, Fantozzi R (2009) PPARγ stimulation promotes neurite outgrowth in SH-SY5Y human neuroblastoma cells. Neurosci Lett 454: 134-138. doi: 10.1016/j.neulet.2009.03.014 PMID: 19429070
19. Moon JH, Kim HJ, Yang AH, Kim HM, Lee BW, et al. (2012) The effect of rosiglitazone on LRP1 expression and amyloid beta uptake in human brain microvascular endothelial cells: A possible role of a lowdose thiazolidinedione for dementia treatment. Int J Neuropsychopharmacol 14: 135-142.
20. Wada K, Nakajima A, Katayama K, Kudo C, Shibuya A, et al. (2006) Peroxisome proliferator-activated receptor γ-mediated regulation of neural stem cell proliferation and differentiation. J Biol Chem 281: 12673-12681. PMID: 16524877
21. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. (2011) Toward defining the preclinical stages of Alzheimer 's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-292. doi: 10.1016/j.jalz.2011.03.003 PMID: 21514248
22. Logothetis NK (2003) The underpinnings of the BOLD functional magnetic resonance imaging signal. J Neurosci 23: 3963-3971. PMID: 12764080
23. Biswal B, Yetkin FZ, Haughton VM, Hyde JS (1995) Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med 34: 537-541. PMID: 8524021
24. Fox MD, Raichle ME (2007) Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 8: 700-711. PMID: 17704812
25. Damoiseaux JS, Prater KE, Miller BL, Greicius MD (2011) Functional connectivity tracks clinical deterioration in Alzheimer's disease. Neurobiol Aging 33: 828.e819-828.e830. doi: 10.1016/j. neurobiolaging.2011.06.025 PMID: 21843906
26. Wang Z, Jia X, Liang P, Qi Z, Yang Y, et al. (2012) Changes in thalamus connectivity in mild cognitive impairment: Evidence from resting state fMRI. Eur J Radiol 81: 277-285. doi: 10.1016/j.ejrad.2010.12. 044 PMID: 21273022
27. Lorenzi M, Beltramello A, Mercuri NB, Canu E, Zoccatelli G, et al. (2011) Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs Aging 28: 205-217. doi: 10.2165/ 11586440-000000000-00000 PMID: 21250762
28. Liang Z, King J, Zhang N (2011) Uncovering intrinsic connectional architecture of functional networks in awake rat brain. J Neurosci 31: 3776-3783. doi: 10.1523/JNEUROSCI.4557-10.2011 PMID: 21389232
29. Liang Z, King J, Zhang N (2012) Anticorrelated resting-state functional connectivity in awake rat brain. NeuroImage 59: 1190-1199. doi: 10.1016/j.neuroimage.2011.08.009 PMID: 21864689
30. Liang Z, Li T, King J, Zhang N (2013) Mapping thalamocortical networks in rat brain using resting-state functional connectivity. NeuroImage 83: 237-244. doi: 10.1016/j.neuroimage.2013.06.029 PMID: 23777756
31. Zhang N, Rane P, Huang W, Liang Z, Kennedy D, et al. (2010) Mapping resting-state brain networks in conscious animals. J Neurosci Methods 189: 186-196. doi: 10.1016/j.jneumeth.2010.04.001 PMID: 20382183
32. Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, et al. (1997) Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47: 29-35. PMID: 9037440
33. Mandrekar-Colucci S, Karlo JC, Landreth GE (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci 32: 10117-10128. doi: 10.1523/JNEUROSCI.5268-11. 2012 PMID: 22836247
34. Beason-Held LL, Goh JO, An Y, Kraut MA, O'Brien RJ, et al. (2013) Changes in brain function occur years before the onset of cognitive impairment. J Neuosci 33: 18008-18014. doi: 10.1523/ JNEUROSCI.1402-13.2013 PMID: 24227712
35. Sanabria-Diaz G, Martinez-Montes E, Melie-Garcia L (2013) Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment. PLoS One 8: e68860. doi: 10.1371/journal.pone.0068860 PMID: 23894356
36. King JA, Garelick TS, Brevard ME, Chen W, Messenger TL, et al. (2005) Procedure for minimizing stress for fMRI studies in conscious rats. J Neurosci Methods 148: 154-160. PMID: 15964078
37. Liang Z, King J, Zhang N (2014) Neuroplasticity to a single-episode traumatic stress revealed by resting-state fMRI in awake rats. NeuroImage 103: 485-491. doi: 10.1016/j.neuroimage.2014.08.050 PMID: 25193500
38. Liang Z, Liu X, Zhang N (2014) Dynamic resting state functional connectivity in awake and anesthetized rodents. NeuroImage 104: 89-99. doi: 10.1016/j.neuroimage.2014.10.013 PMID: 25315787
39. Swanson LW (2004) Brain Maps: Structure of the Rat Brain. A Laboratory Guide with Printed and Electronic Templates for Data, Models and Schematics Amsterdam: Elsevier. 215 p.
40. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, et al. (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270-279. doi: 10.1016/j.jalz.2011.03.008 PMID: 21514249
41. Crenshaw DG, Gottschalk WK, Lutz MW, Grossman I, Saunders AM, et al. (2013) Using genetics to enable studies on the prevention of Alzheimer' s disease. Clin Pharmacol Ther 93: 177-185. doi: 10.1038/clpt.2012.222 PMID: 23249780
42. Pflanzner T, Janko MC, Andre-Dohmen B, Reuss S, Weggen S, et al. (2011) LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol Aging 32: 2323 e2321-2311.
43. Landreth G, Jiang Q, Mandrekar S, Heneka M, Landreth G, et al. (2008) PPARγ agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5: 481-489. doi: 10.1016/j.nurt.2008. 05.003 PMID: 18625459
44. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz MD, et al. (1996) Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Commun 224: 431-437. PMID: 8702406
45. Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M, et al. (2005) Peroxisome proliferatoractivated receptor γ is expressed in hippocampal neurons and its activation prevents β-amyloid neurodegeneration: role ofWnt signaling. Exp Cell Res 304: 91-104. PMID: 15707577
46. Kummer MP, Heneka MT (2008) PPARs in Alzheimer's disease. PPAR Research. pp. 8.
47. Sarruf DA, Yu F, Nguyen HT, Williams DL, Printz RL, et al. (2009) Expression of peroxisome proliferatoractivated receptor-γ in key neuronal subsets regulating glucosemetabolismand energy homeostasis. Endocrinology 150: 707-712. doi: 10.1210/en.2008-0899 PMID: 18845632
48. Akram A, Schmeidler J, Katsel P, Hof P, Haroutunian V (2010) Increased expression of RXRα in dementia: an early harbinger for the cholesterol dyshomeostasis? Mol Neurodegener 5: 36. doi: 10.1186/ 1750-1326-5-36 PMID: 20843353
49. Moreno S, Farioli-Vecchioli S, Ceru MP (2004) Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123: 131-145. PMID: 14667448
50. Liang Z, King J, Zhang N (2012) Intrinsic organization of the anesthetized brain. J Neurosci 32: 10183-10191. doi: 10.1523/JNEUROSCI.1020-12.2012 PMID: 22836253
51. Chang C, Glover GH (2009) Effects of model-based physiological noise correction on default mode network anti-correlations and correlations. Neuroimage 47: 1448-1459. doi: 10.1016/j.neuroimage.2009. 05.012 PMID: 19446646
52. Kalthoff D, Seehafer JU, Po C, Wiedermann D, Hoehn M (2011) Functional connectivity in the rat at 11.7T: Impact of physiological noise in resting state fMRI. Neuroimage 54: 2828-2839. doi: 10.1016/j. neuroimage.2010.10.053 PMID: 20974263
53. Vemuri P, Jones D, Jack C (2011) Resting state functional MRI in Alzheimer's disease. Alzheimers Res Ther 4: 2.
54. Sheline YI, Raichle ME (2013) Resting state functional connectivity in preclinical Alzheimer's Disease. Biol Psychiatry 74: 340-347. doi: 10.1016/j.biopsych.2012.11.028 PMID: 23290495
55. Machulda MM, Jones DT, Vemuri P, McDade E, Avula R, et al. (2011) Effect of APOE ε4 status on intrinsic network connectivity in cognitively normal elderly subjects. Arch Neurol 68: 1131-1136. doi: 10.1001/archneurol.2011.108 PMID: 21555604
56. Sheline YI, Morris JC, Snyder AZ, Price JL, Yan Z, et al. (2010) APOE4 Allele Disrupts Resting State fMRI Connectivity in the Absence of Amyloid Plaques or Decreased CSF Aβ42. J Neurosci 30: 17035-17040. doi: 10.1523/JNEUROSCI.3987-10.2010 PMID: 21159973
57. Derosa G (2010) Efficacy and tolerability of pioglitazone in patients with Type 2 Diabetes Mellitus. Drugs 70: 1945-1961. doi: 10.2165/11538100-000000000-00000 PMID: 20883052
58. Miyazaki Y, Matsuda M, DeFronzo RA (2002) Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25: 517-523. PMID: 11874940